Oncology

Recommended levels of exercise found to decrease the risk of cancer in 13 of 26 cancer types.

Certain cancer cells evade the immune system through blocking NLRC5.

Issues with sleep can lead poor prognosis for skin cancer.

Several factors can affect whether women diagnosed with breast cancer begin chemotherapy.

Nanostructured lipid carriers containing melatonin adjuvant to tamoxifen killed more breast cancer cells than tamoxifen alone.

Hyaluronidase could stop elevated pressure in solid tumors, which is a major reason cancer drugs fail.

Patients with cancer need to be assessed for mental health issues.

Differences exist between cancer in males and females on a molecular level.

Quality measures for the management of NSCLC patients are only received by 13% of all eligible patients.

Microfluidic device can help physicians determine optimal treatment of cancer.

Patients with 2a testicular seminoma show improved outcomes with radiation.

Discovery may determine the best therapeutic option for breast cancer patients.

Up to 25% of patients with lung cancer also have an autoimmune disease.

Treatment attacks brain tumor metabolism at several points.

The Comparative Toxicogenomics Database is able to identify genetically similar diseases and could repurpose medications to treat these conditions.

Top news of the day from across the health care landscape.

A large proportion of cancer patients carry genetic variants of unknown significance.

Inhibiting TGF-beta Receptor Type 1 may have a negative impact on breast cancer therapy.

Improved response rates and extended periods of disease remission found with precision medicine.

Nivolumab blocks the activation of the protein PD-1 to prompt an attack by the immune system.

Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate that binds to a protein highly expressed in about two-thirds of SCLC tumors.

Providers need to better inform patients about the risks of heart disease compared with breast cancer.

Rovalpituzumab tesirine is an antibody-drug conjugate that binds to a protein highly expressed in about two-thirds of SCLC tumors.

Patients who underwent surgery and then standard treatment lived 9 months longer than patients who just had the standard treatment.

The compound 2-bromo-palmitate has the ability to inhibit EGFR.

Pembrolizumab found to prevent disease progression in 54.5% of patients with advanced thyroid cancer.

Patients with squamous cell mouth cancer with an expressed spectrin gene have a 4.6 times higher death rate.

Recent advances and updates in oncology and cancer drug development.